Ronni helps pharmaceutical companies respond strategically when their products are challenged in litigation or regulatory actions. She also is experienced in advising clients on related securities disclosure policies and shareholder demands, as well as issues involving the promotion of pharmaceuticals and devices.
Located in:
Areas of Focus:
Ronni represents pharmaceutical and medical device companies as a litigator and as a counselor. She draws on more than 25 years of experience in product liability, consumer fraud and securities suits, government investigations, and congressional and regulatory inquiries to assess risks and defend companies.
Ronni represents clients in personal injury actions, formulating litigation and settlement strategy through assessing internal documents, interviewing fact witnesses, analyzing medical literature, and developing and presenting expert witnesses. She works extensively with in-house research and development personnel both to investigate factual allegations and to prepare witnesses for testimony. She has identified, worked with and deposed expert witnesses in myriad fields, including biostatisticians, clinical trialists, surgeons, cardiologists, neurologists, oncologists, hematologists, pharmacologists, and toxicologists. Ronni provides scientific and expert support to government investigations and securities teams, as well as to other firms in virtual law firm arrangements.
Ronni counsels clients on regulatory and compliance issues relating to clinical trials, transparency, and informed consent. She counsels companies prior to product approval as well as in response to challenges, such as adverse event reports, results from clinical trials and regulatory actions, and reviews regulatory filings.
Representative matters may include engagements before joining Troutman Pepper.
Firm News
08.08.23
Troutman Pepper Attorneys Named to 2022 Capital Pro Bono Honor Roll
Sponsored Events
07.26.23
American Conference Institute's (ACI) 2023 Women Life Sciences Leaders Summit
Speaking Engagements
10.26.22
Medmarc Webinar: Increasing Diversity in Clinical Trials: FDA Guidance and Industry Efforts
Sponsored Events
07.27.22
Women Leaders in Life Sciences Law
Articles + Publications
06.14.22
FDA Draft Guidance Instructs Sponsors on Content and Timing of Diversity Plans for Clinical Trials
Articles + Publications
01.27.22
FDA Enforces ClinicalTrials.gov Results Posting Requirements, Including Threats of Financial Penalty